Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.83 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL27715026 | 0.94 | GSR (0.95) | GSRARG2ARG1CYP1A2RNPEP | |
| Lysine SCHEMBL3359527 | 0.91 | GSR (1.00) | GSRARG2ARG1CYP1A2RNPEP | |
| Lysine SCHEMBL456381 | 0.91 | GSR (1.00) | GSRARG2ARG1CYP1A2RNPEP | |
| Lysine SCHEMBL1645 | 0.91 | GSR (1.00) | GSRARG2ARG1CYP1A2RNPEP | |
| Lysine SCHEMBL7343 | 0.91 | GSR (1.00) | GSRARG2ARG1CYP1A2RNPEP | |
| Lysine SCHEMBL668975 | 0.91 | GSR (1.00) | GSRARG2ARG1CYP1A2RNPEP | |
| Lysine SCHEMBL15303774 | 0.91 | GSR (1.00) | GSRARG2ARG1CYP1A2RNPEP | |
| Lysine SCHEMBL1000151 | 0.91 | GSR (1.00) | GSRARG2ARG1CYP1A2RNPEP | |
| Lysine SCHEMBL2802757 | 0.91 | GSR (1.00) | GSRARG2ARG1CYP1A2RNPEP | |
| Lysine SCHEMBL9439278 | 0.91 | GSR (1.00) | GSRARG2ARG1CYP1A2RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024017165-A1 | METHOXYPOLYETHYLENE GLYCOL-POLY(LACTIC-CO-GLYCOLIC ACID)-POLYLYSINE-BASED DEVELOPING POROUS MICROSPHERE, PREPARATION METHOD, AND USE | 森心(上海)科技有限公司 | 2024-01-25 | — | — | WO | claimed |
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | AMGEN INC. | 2023-03-16 | — | — | US | claimed |
| EP-4103235-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | Amgen Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| CN-115279404-A | Formulation of human anti-TSLP antibodies and methods of treating inflammatory diseases | 安进公司 | 2022-11-01 | — | — | CN | claimed |
| CN-115252877-A | Iodopolyethylene glycol-polylactic glycolic acid-polylysine development porous microsphere, preparation method and application | 上海市肿瘤研究所 | 2022-11-01 | — | — | CN | claimed |
| WO-2021163504-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | AMGEN INC. (US) | 2021-08-19 | — | — | WO | claimed |
| CN-101732723-B | Polyethylene glycol-poly(lactic-co-glycolic acid)-polylysine nano-delivery system, preparation method and application thereof | SHANGHAI CANCER INST | 2012-07-25 | — | — | CN | claimed |
| CN-101732723-A | Polyethylene glycol-poly(lactic-co-glycolic acid)-polylysine nano-delivery system, preparation method and application thereof | SHANGHAI CANCER INST | 2010-06-16 | — | — | CN | claimed |
| WO-2024017165-A1 | METHOXYPOLYETHYLENE GLYCOL-POLY(LACTIC-CO-GLYCOLIC ACID)-POLYLYSINE-BASED DEVELOPING POROUS MICROSPHERE, PREPARATION METHOD, AND USE | 森心(上海)科技有限公司 | 2024-01-25 | — | — | WO | disclosed |
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | AMGEN INC. | 2023-03-16 | — | — | US | disclosed |
| EP-4103235-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | Amgen Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115279404-A | Formulation of human anti-TSLP antibodies and methods of treating inflammatory diseases | 安进公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115252877-A | Iodopolyethylene glycol-polylactic glycolic acid-polylysine development porous microsphere, preparation method and application | 上海市肿瘤研究所 | 2022-11-01 | — | — | CN | disclosed |
| CN-115177747-A | Polyethylene glycol-polylactic glycolic acid-polylysine/barium sulfate development porous microsphere, preparation method and application | 上海市肿瘤研究所 | 2022-10-14 | — | — | CN | disclosed |
| WO-2021163504-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | AMGEN INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| CN-101732723-B | Polyethylene glycol-poly(lactic-co-glycolic acid)-polylysine nano-delivery system, preparation method and application thereof | SHANGHAI CANCER INST | 2012-07-25 | — | — | CN | disclosed |
| CN-102600474-A | Application of polyethylene glycol-polylactic-co-glycolic acid-poly-L-lysine block polymer in delivery drugs or genes | SHANGHAI CANCER INST | 2012-07-25 | — | — | CN | disclosed |
| CN-101732723-A | Polyethylene glycol-poly(lactic-co-glycolic acid)-polylysine nano-delivery system, preparation method and application thereof | SHANGHAI CANCER INST | 2010-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | TSLP, IL5, ORAI1 | GSR 4256/4885ARG2 2715/4885ARG1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.